ACH-1625: Preliminary Phase Ib data

Achillion reported preliminary data from the third and fourth dosing cohorts of the Phase Ib portion of a double-blind, European Phase Ia/Ib trial. In 9 patients in the third cohort, 200 mg oral ACH-1625 twice daily for 5 days reduced HCV RNA levels by 3.86 log10 vs. 0.16 log10 for placebo. A sustained reduction in HCV RNA levels of 1.65 log10 from baseline was maintained through day 12.

In 8 patients in the fourth cohort, 600 mg oral ACH-1625 once daily for 5 days reduced HCV RNA levels by 3.81 log10 vs. 0.24 log10 for placebo. A sustained reduction in HCV RNA levels of 2.19 log10 from baseline was maintained through day 12. ...